Trial Profile
A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Subjects With Relapsed/Refractory Large B-Cell Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 23 Dec 2022
Price :
$35
*
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Utomilumab (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma; Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms ZUMA-11
- Sponsors Kite Pharma
- 21 Dec 2022 Status changed from active, no longer recruiting to discontinued.
- 06 Dec 2022 Planned End Date changed from 1 Sep 2022 to 1 Dec 2022.
- 11 May 2022 Planned End Date changed from 1 Jun 2022 to 1 Sep 2022.